Patent: 7,923,008
✉ Email this page to a colleague
Summary for Patent: 7,923,008
Title: | Methods for decreasing osteoclast formation or bone resorption using an antibody to osteoprotegerin binding protein |
Abstract: | A novel polypeptide, osteoprotegerin binding protein, involved in osteolcast maturation has been identified based upon its affinity for osteoprotegerin. Nucleic acid sequences encoding the polypeptide, or a fragment, analog or derivative thereof, vectors and host cells for production, methods of preparing osteoprotegerin binding protein, and binding assays are also described. Compositions and methods for the treatment of bone diseases such as osteoporosis, bone loss due to arthritis or metastasis, hypercalcemia, and Paget\'s disease are also provided. |
Inventor(s): | Boyle; William J. (Moorpark, CA) |
Assignee: | Amgen Inc. (Thousand Oaks, CA) |
Application Number: | 11/336,067 |
Patent Claims: | see list of patent claims |
Details for Patent 7,923,008
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Amgen, Inc. | PROLIA | denosumab | Injection | 125320 | 06/01/2010 | ⤷ Try a Trial | 2017-04-16 |
Amgen, Inc. | XGEVA | denosumab | Injection | 125320 | 11/18/2010 | ⤷ Try a Trial | 2017-04-16 |
Nps Pharmaceuticals, Inc. | NATPARA | parathyroid hormone | For Injection | 125511 | 01/23/2015 | ⤷ Try a Trial | 2017-04-16 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 7,923,008
Country | Patent Number | Estimated Expiration |
---|---|---|
Austria | 363533 | ⤷ Try a Trial |
Australia | 2005201799 | ⤷ Try a Trial |
Australia | 2008202516 | ⤷ Try a Trial |
Australia | 2011202547 | ⤷ Try a Trial |
Australia | 2013204967 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |